FDA panel fails to back Merck & Co.'s Proscar, GlaxoSmithKline's Avodart - FirstWord
Links shared publicly online about this topic.
- 686total visits
FDA panel fails to back Merck & Co.'s Proscar, GlaxoSmithKline's Avodart - FirstWord
View full resource at firstwordplus.com
Tags: Prostate Cancer, Prostate, Benign Prostatic Hypertrophy Medication, Men's Health, FDA, Proscar, Merck & Co.
Most Recently Shared on December 1, 2010 at 10:42 pm By:
RT @fwpharma: FDA panel fails to back Merck's Proscar for prevention of prostate cancer http://bit.ly/hkDIP0
FDA panel backs Glaxo drug for rare cancer | ajc.com
ajc.com — “WASHINGTON — A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease.” View full resource at ajc.com
Most Recently Shared on March 21, 2012 at 4:29 pm By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
FDA panel backs Glaxo drug for rare cancer - Atlanta Journal Constitution http://t.co/p4jwFZcO #medicine
FDA Backs Glaxo Drug For Rare Cancer | ThirdAge
thirdage.com — “ A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at thirdage.com
Most Recently Shared on March 21, 2012 at 12:19 am By:
FDA Backs Glaxo Drug For Rare Cancer http://t.co/QMfj2u64
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 6:57 pm By:
FDA panel backs Glaxo drug for rare sarcoma cancer: A panel of cancer experts voted against an experimental Merc... http://t.co/CS4hfxkn
FDA Panel Rejects Merck Drug for Sarcoma, but Backs Glaxo's Votrient - WSJ.com
online.wsj.com — “A federal advisory panel rejected an experimental Merck & Co. drug for use in patients with soft-tissue or bone sarcomas—on concerns that it didn't work well enough to offset potentially serious side effects—while backing a different drug from GlaxoSmithKline.” View full resource at online.wsj.com
Most Recently Shared on March 20, 2012 at 5:37 pm By:
FDA Panel Backs Glaxo Drug for Sarcoma http://t.co/Cc9B6D9P
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 5:29 pm By:
HealthTrendster Health Executive
FDA panel backs Glaxo drug for rare sarcoma cancer - A panel of cancer experts has backed the benefits of a GlaxoSmi... http://t.co/k7JJ13Oc
Merck’s cholesterol lowering drug gets FDA panel’s vote
news-medical.net — “A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.” View full resource at news-medical.net
Most Recently Shared on November 4, 2011 at 12:49 am By:
Merck’s cholesterol lowering drug gets FDA panel’s vote: A health advisors’ panel have unanimously backed the us... http://t.co/G2OpFf7N
UPDATE: FDA Panel Backs Approval Of Vertex's Hepatitis C Drug - FoxNews.com
foxnews.com — “A Food and Drug Administration panel unanimously backed the approval of Vertex Pharmaceuticals Inc.'s proposed hepatitis C-drug telaprevir, saying it showed strong effectiveness, a day after also endorsing a similar product from Merck & Co.” View full resource at foxnews.com
Most Recently Shared on April 29, 2011 at 7:54 pm By:
Health,Fitness,Diet Health Business
UPDATE: FDA Panel Backs Approval Of Vertex's Hepatitis C Drug http://bit.ly/iSysXD
Merck Wins U.S. FDA Panel--™s Backing for Hepatitis C Drug - Bloomberg
bloomberg.com — “Merck & Co. won a U.S. panel--™s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.” View full resource at bloomberg.com
Most Recently Shared on April 28, 2011 at 11:20 am By:
John Carroll Health Communicator
In case you missed it, Merck gets unanimous panel support on boceprevir; list of suggested post-marketing studies. http://bloom.bg/iwYpxP
FDA panel backs Merck hepatitis drug | Reuters
reuters.com — “SILVER SPRING, Maryland (Reuters) - A Merck & Co drug that boosts the chance of curing hepatitis C infection moved closer to the U.S. market on Wednesday as an advisory panel unanimously recommended” View full resource at reuters.com
Most Recently Shared on April 27, 2011 at 8:31 pm By:
Bruce McLucas, MD Doctor, ObGyn Physician, Surgeon, and Physician
US FDA panel backs Merck hepatitis drug http://ow.ly/1cn94b
FDA panel backs Merck hepatitis drug | Reuters
reuters.com — “SILVER SPRING, Maryland (Reuters) - A Merck & Co drug that boosts the chance of curing hepatitis C infection moved closer to the U.S. market on Wednesday as an advisory panel unanimously recommended” View full resource at reuters.com
Most Recently Shared on April 27, 2011 at 8:17 pm By:
US FDA panel backs Merck hepatitis drug http://reut.rs/m9ERc1
FDA panel backs Merck hepatitis drug | Reuters
in.reuters.com — “SILVER SPRING, Maryland (Reuters) - A Merck & Co drug that boosts the chance of curing hepatitis C infection moved closer to the U.S. market on Wednesday as an advisory panel unanimously recommended” View full resource at in.reuters.com
Most Recently Shared on April 27, 2011 at 8:11 pm By:
eyeonfda Pharma and Health Lawyer
RT @rtrsin_health: US FDA panel backs Merck hepatitis drug http://reut.rs/lrHJnz
FDA panel backs Merck hepatitis drug
health.yahoo.net — “A Merck & Co drug that boosts the chance of curing hepatitis C infection moved closer to the U.S. market on Wednesday as an advisory panel unanimously recommended approval.” View full resource at health.yahoo.net
Most Recently Shared on April 27, 2011 at 4:00 pm By:
Jane Anderson Healthy Eating Advisor
Merck pitches hepatitis C drug to U.S. FDA panel http://bit.ly/fhOHAn
FDA panel backs Merck hepatitis drug
health.yahoo.net — “A Merck & Co drug that boosts the chance of curing hepatitis C infection moved closer to the U.S. market on Wednesday as an advisory panel unanimously recommended approval.” View full resource at health.yahoo.net
Most Recently Shared on April 27, 2011 at 3:39 pm By:
Jennifer Ann Grisso Nurse and Active Health Library
Merck pitches hepatitis C drug to U.S. FDA panel: An experimental drug for the liver-damaging hepatitis C virus ... http://bit.ly/g2QI1D
Merck KGaA Fails to Win FDA's Backing for Pill Against Multiple Sclerosis - Bloomberg
bloomberg.com — “Merck KGaA failed to win U.S. regulators--™ backing for its multiple sclerosis pill cladribine, shutting the German drugmaker for now out of the market for new treatments for the crippling disease.” View full resource at bloomberg.com
Most Recently Shared on March 2, 2011 at 8:37 am By:
Merck KGaA Fails to Win FDA's Backing for Pill Against Multiple Sclerosis: U.S. regulators requested more info... http://bloom.bg/hD5BuZ
Advertisement
